Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation.
PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration
Vivet is very happy to share the March 2020
Vivet Announces Publication in Nature Communications of Preclinical Data from VTX-803
Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics
PARIS, France June 12th, 2018, Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare
PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017's
Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation
PARIS, France September 26th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product
In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However, as many as 30 million people may suffer from one of the more than 6,000 existing rare diseases.